Telix Pharmaceuticals updates Illuccix China trial, FDA plans
Telix (ASX: TLX, NASDAQ: TLX) provided a precision medicine portfolio update on Dec 21, 2025 covering three PET imaging candidates. TLX591-CDx (Illuccix): Phase 3 China study (n=140) met its primary endpoint with overall patient-level PPV 94.8% (95% CI: 85.9%, 98.2%), region-level PPV 100% in prostate bed and non-bone metastases, and…